

07/236,724

ATTORNEY DOCKET NO.: 061635-0007

U.S. Patent No. 4,937,078

Page 1

DAC
JFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Number 4,937,078)
Granted: June 26, 1990)
Patentees: Michael MEZEI and Adrienn)
GESZTES)
Assignee: Lipoderm Pharmaceuticals Ltd.)
For: LIPOSOMAL LOCAL)
ANESTHETIC AND ANALGESIC)
PRODUCTS)
)
Docket No.: 04E-0389

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Patent Ext.
Randolph Building
Alexandria, VA 22314

Date: December 1, 2005

**REQUEST FOR CORRECTION OF ASSIGNEE IN PENDING APPLICATION
FOR EXTENSION OF PATENT TERM PURSUANT TO 35 U.S.C. § 156**

Dear Sir:

A Request for Extension of Patent Term Pursuant to 35 U.S.C. § 156 was submitted to the United States Patent and Trademark Office on July 7, 2004 requesting extension of patent term for United States patent number 4,937,078 ("Request"). It has recently come to the attention of current assignee, Lipoderm Pharmaceuticals Ltd., that the Request was submitted in the name of the former assignee, Mezei Associates, Ltd.

In a letter, dated April 8, 2005 from Jane A Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research, Ms. Axelrad advised that NADA

number 141-186, for the animal drug product Surpass (diclofenac sodium) was approved on May 13, 2004 and the submission of the of the patent term extension application on June [sic] 7, 2004 was timely within the meaning of 35 U.S.C. § 156. (See April 8, 2005 Letter Attached as Exhibit A).

In a letter, dated July 18, 2005, from Karin Ferriter, Senior Legal Advisor, Office of Patent Legal Administration to Ms. Axelrad, Ms. Ferriter acknowledged that United States patent number 4,937,078 was eligible for patent term restoration and requested Ms. Axelrad to determine the applicable regulatory review period. (See July 18, 2005 Letter attached as Exhibit B).

Applicant, Lipoderm Pharmaceuticals Ltd., a corporation created and existing under the Laws of Canada, represents that it is the owner of the entire interest in and to United States Patent Number 4,937,078 for LIPOSOMAL LOCAL ANESTHETIC AND ANALGESIC PRODUCTS, granted to Michael MEZEI and Adrienn GESZTES on June 26, 1990, by virtue of an assignment from Mezei Associates Ltd. to Lipoderm Pharmaceuticals Ltd., dated April 17, 1997 ("Lipoderm Assignment"). The Lipoderm Assignment was submitted for recordation by facsimile to the U.S. Patent and Trademark Office Assignment Recordation Department on November 30, 2005. A copy of the Assignment, the Recordation Form Cover Sheet, the facsimile cover sheet, and the facsimile transmittal acknowledging submission are attached as Exhibit C.

A Grant of Power of Attorney, authorizing the registered practitioners of Morgan, Lewis & Bockius LLP associated with customer number 009629, to act on behalf of Lipoderm Pharmaceuticals Ltd. for the purpose of obtaining a patent term extension for United States patent number 4,937,078 is attached as Exhibit D.

In accordance with the Grant of Power of Attorney, please address all inquiries
and correspondence relating to this application for patent term extension to:


Victor N. Balancia
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Telephone: 202-739-5667
Facsimile: 202-739-3001

The Commissioner is hereby authorized by this paper to charge any fees during
the entire pendency of this Request including fees due and any required extension of time
fees, or credit any overpayment to Deposit Account 50-0310.

Respectfully Submitted,
Morgan, Lewis & Bockius LLP

Date: December 1, 2005

Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000



Victor N. Balancia
Registration No. 31,231
Tel. No.: (202) 739-5656
Fax No.: (202) 739-3001




DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

VNB
DLF

Food and Drug Administration
Rockville MD 20857

Re: Surpass
Docket No. 04E-0389



The Honorable Jon Dudas

Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

APR 8 2005

61635-5007

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 4,937,078 filed by Mezei Associates, Ltd. under 35 U.S.C. § 156. The animal drug product claimed by the patent is Surpass (diclofenac sodium), which was assigned NADA No. 141-186.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The NADA was approved on May 13, 2004, which makes the submission of the patent term extension application on June 7, 2004, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad


Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Paul E. Dietze VNB
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Ave., NW
Washington, DC 20004



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 18 2005



VVB/DLF
Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
HFD - 13
5600 Fishers Lane,
Rockville, MD 20857

Attention: Claudia Grillo

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 4,937,078. The application was filed on June 7, 2004, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571)272-7744 (telephone) or (571)273-7744 (facsimile).

Karin Ferriter

Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Paul E. Dietze
Morgan, Lewis & Bockius, LLP
1111 Pennsylvania Ave., NW
Washington DC 20004

RE: Surpass® (diclofenac sodium)
Docket No. 04E-0389

RECEIVED

JUL 21 2005

MORGAN, LEWIS & BOCKIUS LLP

D. C. GRIFFIN
By BLC Date 7/21/05



- 4 -

Schedule "A"

ASSIGNMENT

The undersigned, MEZEL ASSOCIATES LTD., whose full post office address is P.O. Box 2255
Halifax, in consideration of the sum of \$1.00 and other good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, does hereby sell, assign and transfer to LIPODERM PHARMACEUTICALS LTD., whose full post office address is P.O. Box 2255, Halifax, Nova Scotia, Canada, B3J 3C8, its successors and assigns forever, all my right, title and interest in, to and under the following patents:

1. United States of America Letters Patent No.4,761,288 granted on the 2nd day of August, 1988;
2. United States of America Letters Patent No.4,897,269 granted on the 30th day of January, 1990;
3. United States of America Letters Patent No.4,937,078 granted on the 26th day of June, 1990;
4. European Letters Patent No.0 177 223 B1 granted on the 28th day of February, 1990;
5. Japanese Letters Patent No.015467 granted in 1990;

the same to be held and enjoyed by LIPODERM PHARMACEUTICALS LTD. to the full end of the term for which the said Letters Patent are granted, as fully and entirely as the same could have been held and enjoyed by MEZEL ASSOCIATES LTD. if this assignment and sale had not been made.

EXECUTED AT NS this 22 day of April, 1997.

SIGNED, SEALED AND DELIVERED.

in the presence of:

Katherine Meyer
Witness

) MEZEL ASSOCIATES LIMITED

Per: Michael Mezel c/s
MICHAEL MEZEL, President

ASSIGN

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

Attorney Docket Number -061635-0007

Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
Randolph Building, Customer Window
Alexandria, VA 22314

Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): MEZEI ASSOCIATES LTD. Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies): Name: LIPODERM PHARMACEUTICALS LTD. Address: P.O. Box 2255, Halifax, Nova Scotia</p>
<p>3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment Merger Security Agreement Change of Name Other </p> <p>Execution Date: <u>April 17 1997</u></p>	<p>Country (if other than USA): Canada B3J 3C8</p>
<p>4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is:</p> <p>A. Patent Application No.(s) B. Patent No. 4,937,078</p> <p>Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	
<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Morgan, Lewis & Bockius LLP 1111 Pennsylvania Avenue, N.W. Washington, DC 20004</p>	<p>6. Number of applications and patents involved: 1</p>
	<p>7. Total fee (37 CFR 3.41): \$40.00 Please charge to the deposit account listed in Section 8.</p>
	<p>8. Deposit account number: 50-0310</p>

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Dean L. Fanelli
Name of Person Signing

48,907
Reg. No. Signature

November 30, 2005
Date

Total number of pages including cover sheet: 2

Mail documents to be recorded with required cover sheet information to:
Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
Randolph Building, Customer Window
Alexandria, VA 22314

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue NW
Washington, D.C. 20004
TEL: 202.739.3000
FAX: 202.739.3001
eFax: 877.432.9652
www.morganlewis.com

Morgan Lewis
COUNSELORS AT LAW

FAXED
Kay

SEND TO

Name: Assignment Recordation Services Firm: U.S. Patent and Trademark Office
FAX #: 571-273-0140 Telephone #:

FROM


Name: Dean L. Fanelli, Ph.D. Floor: 3rd
Operator Sending: Telephone #: (202) 739-5656
FAX #: (202) 739-3001 Date Sent: November 30, 2005 Number of Pages: 3
(including cover page)

COMMENTS

U.S. Patent No. 4,937,078
U.S. Patent Application No. 08/236,724
Issued: June 26, 1990
Inventors: Michael Mezei and Adrienn Gesztes
Filed: August 26, 1988
Title: Liposomal Local Anesthetic and Analgesic Products
Attorney Docket: 061635-0007

Certificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the attached Recordation Form Cover Sheet and Assignment document are being transmitted via facsimile to the Assignment Recordation Services at the U.S. Patent Office on Thursday, September 30, 2004. Applicants request that the attached Assignment be recorded by the U.S. Patent Office.



Dean L. Fanelli
Registration No. 48,907

FAX MESSAGE

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE NAMED RECIPIENT(S). THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

JOB #539

DATE	TIME	TO/FROM	MODE	MIN/SEC	PGS	STATUS
001 11/30	13:05	15665003#15712730140#	EC--S	01' 02"	003	OK

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue NW
Washington, D.C. 20004
TEL: 202.739.3000
FAX: 202.739.3001
eFax: 877.432.9652
www.morganlewis.com

Morgan Lewis
COUNSELORS AT LAW

SEND TO

Name: Assignment Recordation Services Firm: U.S. Patent and Trademark Office
FAX #: 571-273-0140 Telephone #:

FROM

Name: Dean L. Fanelli, Ph.D. Floor: 3rd
Operator Sending: WB Telephone #: (202) 739-5656
FAX #: (202) 739-3001 Date Sent: November 30, 2005 Number of Pages: 3
(including cover page)

FAX MESSAGE

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE NAMED RECIPIENT(S). THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY INFORMED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRONGLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

COMMENTS

U.S. Patent No. 4,937,078
U.S. Patent Application No. 08/236,724
Issued: June 26, 1990
Inventors: Michael Mezel and Adrienn Geztesy
Filed: August 26, 1988
Title: Liposomal Local Anesthetic and Analgesic Products
Attorney Docket: 061635-0007

Certificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the attached Recordation Form Cover Sheet and Assignment document are being transmitted via facsimile to the Assignment Recordation Services at the U.S. Patent Office on Thursday, September 30, 2004. Applicants request that the attached Assignment be recorded by the U.S. Patent Office.

Dean L. Fanelli
Registration No. 48,907

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

United States Patent No.: 4,937,078

Issued: June 26, 1990

Inventors: Michael Mezei and Adrienn Gesztes

For: LIPOSOMAL LOCAL ANESTHETIC
AND ANALGESIC PRODUCTS

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

GRANT OF POWER OF ATTORNEY

The undersigned:

LIPODERM PHARMACEUTICALS LTD., Nova Scotia, Canada, a corporation of Canada hereby appoint(s) the following persons as agent:

BALANCIA, Victor; BEARDELL, Louis W.; BIRD, Donald J.; GAYBRICK, Robert J.; GOLUB, Daniel H.; GOODWYN, R. Tyler; KOKULIS, Paul N.; MCCUTCHEON, Nathan W.; ZELE, John D.; BOSWELL, Mary Jane; BRETSCHER, Carl P.; HAYDEN, Christopher G.; WEIMAR, Elizabeth C.; ANTONELLI, Arthur; BASSON, Kent E.; DAVIS, Kenneth J.; FANELLI, Dean L.; GOODELL, Robert J.; HALLIDAY, Christopher I.; HOLLINGSHEAD, Robert J.; KOENIGBAUER, Fabian M.; LOWEN, Gregory T.; MAURER, Eric J.; MCLEOD, Bonnie W.; NELSON, Thomas E.; PARK, Collin W.; REED, James L.; SMYTH, Robert J.; SULLIVAN, Mark J.; TAYLOR, Todd P.; TENG, Sally P.; WEISBERG, Alison; all of MORGAN, LEWIS & BOCKIUS LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 United States of America


for the purpose of obtaining a patent term extension for United States patent no. 4,937,078. Assignee further directs that all correspondence for this matter be addressed to the Customer Number given below:

Customer Number: 009629

Please direct all inquiries to:

Victor N. Balancia
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Telephone: (202) 739-5667

The undersigned certifies that he is empowered to act on behalf of **LIPODERM PHARMACEUTICALS LTD.**, in this matter. The undersigned hereby certifies that **LIPODERM PHARMACEUTICALS LTD.**, has the entire right, title and interest in the above-identified United States patent by virtue of an assignment dated April 17, 1997 from Michael Mezei President of **MEZEI ASSOCIATES LTD.**

Signature for Applicant: 

Title: President

Address: 1507 Grant Rd

Cornwall, On

K6J-1Z6 Canada

Date: Nov 15/05